Apr 15, 2013 | Applied Clinical Trials
NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a...
NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease NeuroDerm, Ltd.
NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for ...
NeuroDerm , Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.
NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for ...
NeuroDerm , Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.